Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 269.5% in September

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 38,800 shares, a growth of 269.5% from the September 15th total of 10,500 shares. Based on an average trading volume of 139,900 shares, the days-to-cover ratio is presently 0.3 days.

Astellas Pharma Price Performance

OTCMKTS ALPMY opened at $11.84 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.72 and a current ratio of 0.90. The business’s fifty day moving average is $11.94 and its 200 day moving average is $10.71. The company has a market capitalization of $21.43 billion, a PE ratio of 169.14 and a beta of 0.37. Astellas Pharma has a fifty-two week low of $9.15 and a fifty-two week high of $14.03.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.24 EPS for the quarter. Astellas Pharma had a return on equity of 7.79% and a net margin of 1.17%. The business had revenue of $3.03 billion for the quarter. Sell-side analysts predict that Astellas Pharma will post 0.54 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.